{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:34:21Z","timestamp":1787776461916,"version":"build-2784847793"},"reference-count":101,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1124\/dmd.123.001430","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T18:50:49Z","timestamp":1706554249000},"page":"479-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Kinase Inhibitors FDA Approved 2018\u20132023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities"],"prefix":"10.1016","volume":"52","author":[{"given":"Bethany D.","family":"Latham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6212-8291","authenticated-orcid":false,"given":"Raeanne M.","family":"Geffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9388-9800","authenticated-orcid":false,"given":"Klarissa D.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.123.001430_bib1","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.3390\/molecules25215004","article-title":"Identification of iminium intermediates generation in the metabolism of tepotinib using LC-MS\/MS: in silico and practical approaches to bioactivation pathway elucidation","volume":"25","author":"Abdelhameed","year":"2020","journal-title":"Molecules"},{"key":"10.1124\/dmd.123.001430_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1124\/dmd.123.001430_bib3","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/jcph.953","article-title":"Population pharmacokinetics of imatinib in Nigerians with chronic myeloid leukemia: clinical implications for dosing and resistance","volume":"57","author":"Adeagbo","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001430_bib4","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/bcp.15084","article-title":"Physiologically based pharmacokinetic model predictions of inter-ethnic differences in imatinib pharmacokinetics and dosing regimens","volume":"88","author":"Adiwidjaja","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001430_bib5","series-title":"Cancer Facts & Figures 2023","year":"2023"},{"key":"10.1124\/dmd.123.001430_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1124\/dmd.123.001430_bib7","article-title":"Overview of drug-drug interactions between ritonavir-boosted nirmatrelvir (Paxlovid) and targeted therapy and supportive care for lung cancer","volume":"4","author":"Anwar","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1124\/dmd.123.001430_bib8","doi-asserted-by":"crossref","first-page":"38733","DOI":"10.1039\/C8RA06709K","article-title":"Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS\/MS: in vitro phase I metabolic investigation","volume":"8","author":"Attwa","year":"2018","journal-title":"RSC Advances"},{"key":"10.1124\/dmd.123.001430_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jpba.2018.07.032","article-title":"LC-MS\/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: in vivo and in vitro metabolic investigation","volume":"160","author":"Attwa","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/dmd.123.001430_bib10","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small molecule kinase inhibitor drugs (1995-2021): medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.123.001430_bib11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/pr.115.011411","article-title":"Role of cytochrome P450 2C8 in drug metabolism and interactions","volume":"68","author":"Backman","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.123.001430_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111701","article-title":"Histone modification in NSCLC: molecular mechanisms and therapeutic targets","volume":"22","author":"Bajbouj","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.123.001430_bib13","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1124\/dmd.122.000829","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of abrocitinib, a selective Janus kinase inhibitor, in humans","volume":"50","author":"Bauman","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001430_bib14","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00280-011-1793-7","article-title":"The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers","volume":"69","author":"Bello","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.123.001430_bib15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-013-2207-9","article-title":"A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers","volume":"72","author":"Bello","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.123.001430_bib16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JGO.19.00380","article-title":"Outcomes in Black and White patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors: insights from two large cohorts","volume":"6","author":"Boss\u00e9","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"10.1124\/dmd.123.001430_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/gim.2016.87","article-title":"Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet Med"},{"key":"10.1124\/dmd.123.001430_bib18","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s12325-019-01198-9","article-title":"The effect of rifampin on the pharmacokinetics and safety of lorlatinib: results of a phase one, open-label, crossover study in healthy participants","volume":"37","author":"Chen","year":"2020","journal-title":"Adv Ther"},{"key":"10.1124\/dmd.123.001430_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cllc.2019.07.003","article-title":"Survival disparities in Black patients with EGFR-mutated non-small-cell lung cancer","volume":"21","author":"Cheng","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1124\/dmd.123.001430_bib20","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.apsb.2017.07.004","article-title":"Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1","volume":"7","author":"Cheng","year":"2017","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/dmd.123.001430_bib21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1124\/dmd.123.001453","article-title":"Innovations, opportunities, and challenges for predicting alteration in drug-metabolizing enzyme and transporter activity in specific populations","volume":"51","author":"Chothe","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001430_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/1078155215577810","article-title":"Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics","volume":"22","author":"Chung","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1124\/dmd.123.001430_bib23","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.123.001430_bib24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/cells8060614","article-title":"Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors","volume":"8","author":"Dai","year":"2019","journal-title":"Cells"},{"key":"10.1124\/dmd.123.001430_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drudis.2014.09.007","article-title":"Individualized dosing of tyrosine kinase inhibitors: are we there yet?","volume":"20","author":"de Wit","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1124\/dmd.123.001430_bib26","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2217\/fon-2021-1475","article-title":"Turalio risk evaluation and mitigation strategy for treatment of tenosynovial giant cell tumor: framework and experience","volume":"18","author":"Dharmani","year":"2022","journal-title":"Future Oncol"},{"key":"10.1124\/dmd.123.001430_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105583","article-title":"EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: from molecular mechanisms to clinical research","volume":"167","author":"Dong","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.123.001430_bib28","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1517\/17425255.2010.506873","article-title":"Metabolism considerations for kinase inhibitors in cancer treatment","volume":"6","author":"Duckett","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.123.001430_bib29","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1158\/0008-5472.CAN-07-1885","article-title":"PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib","volume":"67","author":"Engelman","year":"2007","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.123.001430_bib34","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bcpt.13088","article-title":"In vitro screening of six protein kinase inhibitors for time-dependent inhibition of CYP2C8 and CYP3A4: possible implications with regard to drug-drug interactions","volume":"123","author":"Filppula","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/dmd.123.001430_bib35","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2217\/fon-2020-0542","article-title":"Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor","volume":"16","author":"Gelderblom","year":"2020","journal-title":"Future Oncol"},{"key":"10.1124\/dmd.123.001430_bib36","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1158\/1535-7163.MCT-07-2232","article-title":"Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor","volume":"7","author":"Gonzales","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.123.001430_bib37","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/cts.12490","article-title":"Precision dosing: public health need, proposed framework, and anticipated impact","volume":"10","author":"Gonzalez","year":"2017","journal-title":"Clin Transl Sci"},{"key":"10.1124\/dmd.123.001430_bib38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.123.001430_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"Cytochrome P-450 3A4: regulation and role in drug metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.123.001430_bib40","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00228-020-02897-x","article-title":"Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study","volume":"76","author":"Han","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001430_bib41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1021\/acs.chemrestox.1c00327","article-title":"Effects of CYP2D6 genetic polymorphism and drug interaction on the metabolism of dacomitinib","volume":"35","author":"Han","year":"2022","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.123.001430_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3892\/ijo.2021.5270","article-title":"Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (review)","volume":"59","author":"He","year":"2021","journal-title":"Int J Oncol"},{"key":"10.1124\/dmd.123.001430_bib42a","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/toxsci\/kfab056","article-title":"Liver Toxicity Observed With Lorlatinib When Combined With Strong CYP3A Inducers: Evaluation of Cynomolgus Monkey as a Nonclinical Model for Assessing the Mechanism of Combinational Toxicity","volume":"182","author":"Hu","year":"2021","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.123.001430_bib43","series-title":"Dossier Assessment","article-title":"Dacomitinib (non-small-cell lung cancer)\u2014benefit assessment according to \u00a735a Social Code Book V.","year":"2019"},{"key":"10.1124\/dmd.123.001430_bib44","doi-asserted-by":"crossref","first-page":"15117","DOI":"10.1002\/cam4.6184","article-title":"Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: a multicenter, phase II trial","volume":"12","author":"Iwasaku","year":"2023","journal-title":"Cancer Med"},{"key":"10.1124\/dmd.123.001430_bib45","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1124\/dmd.122.001066","article-title":"Novel approaches to characterize individual drug metabolism and advance precision medicine","volume":"51","author":"Jackson","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001430_bib46","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3390\/ijms19082367","article-title":"Role of cytochrome P450 enzymes in the metabolic activation of tyrosine kinase inhibitors","volume":"19","author":"Jackson","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.123.001430_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113796","article-title":"Is there enough evidence to classify cycloalkyl amine substituents as structural alerts?","volume":"174","author":"Kalgutkar","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.123.001430_bib48","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/ni0403-313","article-title":"The role of PI3K in immune cells","volume":"4","author":"Koyasu","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1124\/dmd.123.001430_bib49","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.123.001430_bib50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"10.1124\/dmd.123.001430_bib51","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/CAD.0000000000001360","article-title":"Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities","volume":"33","author":"Kwok","year":"2022","journal-title":"Anticancer Drugs"},{"key":"10.1124\/dmd.123.001430_bib52","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/FPC.0b013e328351d47f","article-title":"PharmGKB summary: very important pharmacogene information for CYP3A5","volume":"22","author":"Lamba","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.123.001430_bib53","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.hoc.2021.03.009","article-title":"The evolving use of phosphatidylinositol 3-kinase inhibitors for the treatment of chronic lymphocytic leukemia","volume":"35","author":"Lampson","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1124\/dmd.123.001430_bib54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10637-019-00745-z","article-title":"A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors","volume":"38","author":"Lee","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1124\/dmd.123.001430_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13629","article-title":"Pexidartinib long-term hepatic safety profile in patients with tenosynovial giant cell tumors","volume":"26","author":"Lewis","year":"2021","journal-title":"Oncologist"},{"key":"10.1124\/dmd.123.001430_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188969","article-title":"Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer: a systematic review and meta-analysis","volume":"1878","author":"Li","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1124\/dmd.123.001430_bib57","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"key":"10.1124\/dmd.123.001430_bib58","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/dmd.109.029660","article-title":"Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases","volume":"38","author":"Liu","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001430_bib59","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","article-title":"Cholestatic hepatitis","year":"2012"},{"key":"10.1124\/dmd.123.001430_bib60","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.123.001430_bib61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2017.01.002","article-title":"Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: implications for hyperbilirubinemia","volume":"129","author":"Miners","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.123.001430_bib62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40268-020-00314-3","article-title":"Pexidartinib (TURALIO\u2122): the first FDA-indicated systemic treatment for tenosynovial giant cell tumor","volume":"20","author":"Monestime","year":"2020","journal-title":"Drugs R D"},{"key":"10.1124\/dmd.123.001430_bib63","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cpt.564","article-title":"Drug-induced liver injury: advances in mechanistic understanding that will inform risk management","volume":"101","author":"Mosedale","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001430_bib64","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.123.001430_bib65","series-title":"Using Population Descriptors in Genetics and Genomics Research: A New Framework for an Evolving Field","year":"2023"},{"key":"10.1124\/dmd.123.001430_bib66","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.pharmtox.45.120403.100058","article-title":"The role of metabolic activation in drug-induced hepatotoxicity","volume":"45","author":"Park","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.123.001430_bib67","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/bjh.18558","article-title":"Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia","volume":"200","author":"Paul","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1124\/dmd.123.001430_bib68","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-21-4176","article-title":"FDA approval summary: belumosudil for adult and pediatric patients 12 years and older with chronic GvHD after two or more prior lines of systemic therapy","volume":"28","author":"Przepiorka","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.123.001430_bib69","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029629","article-title":"Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: a case report","volume":"101","author":"Qiao","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1124\/dmd.123.001430_bib70","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1177\/10781552221139773","article-title":"Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib","volume":"29","author":"Qiu","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"10.1124\/dmd.123.001430_bib71","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/cncr.34104","article-title":"Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing","volume":"128","author":"Reizine","year":"2022","journal-title":"Cancer"},{"key":"10.1124\/dmd.123.001430_bib72","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","article-title":"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib","volume":"12","author":"Riely","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.123.001430_bib73","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/cvr\/cvz013","article-title":"A current understanding of drug-induced QT prolongation and its implications for anticancer therapy","volume":"115","author":"Roden","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1124\/dmd.123.001430_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106552","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update","volume":"187","author":"Roskoski","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.123.001430_bib75","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1124\/jpet.121.000828","article-title":"Novel bile acid-dependent mechanisms of hepatotoxicity associated with tyrosine kinase inhibitors","volume":"380","author":"Saran","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.123.001430_bib76","doi-asserted-by":"crossref","first-page":"10224","DOI":"10.1021\/acs.jmedchem.0c00898","article-title":"DFG-1 residue controls inhibitor binding mode and affinity, providing a basis for rational design of kinase inhibitor selectivity","volume":"63","author":"Schr\u00f6der","year":"2020","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.123.001430_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1089066","article-title":"Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer","volume":"13","author":"Singh","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1124\/dmd.123.001430_bib78","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1124\/dmd.123.001430_bib79","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/jcph.1621","article-title":"Metabolism, excretion, and pharmacokinetics of lorlatinib (PF-06463922) and evaluation of the impact of radiolabel position and other factors on comparability of data across 2 ADME studies","volume":"60","author":"Stypinski","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001430_bib80","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00280-022-04429-z","article-title":"Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl","volume":"89","author":"Sun","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.123.001430_bib81","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1186\/1471-2407-12-568","article-title":"Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer","volume":"12","author":"Suzumura","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1124\/dmd.123.001430_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115336","article-title":"Metabolic activation of drugs by cytochrome P450 enzymes: biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation","volume":"206","author":"Tang","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.123.001430_bib83","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1021\/acs.chemrestox.1c00178","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 and 3A5 by the fibroblast growth factor receptor inhibitor erdafitinib","volume":"34","author":"Tang","year":"2021","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.123.001430_bib84","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1124\/dmd.121.000508","article-title":"Infigratinib is a reversible inhibitor and mechanism-based inactivator of cytochrome P450 3A4","volume":"49","author":"Tang","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001430_bib85","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1124\/dmd.121.000804","article-title":"Direct and sequential bioactivation of pemigatinib to reactive iminium ion intermediates culminates in mechanism-based inactivation of cytochrome P450 3A","volume":"50","author":"Tang","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001430_bib86","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41397-019-0092-2","article-title":"HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis","volume":"20","author":"Tangamornsuksan","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.123.001430_bib87","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"10.1124\/dmd.123.001430_bib88","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/bcp.12496","article-title":"Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations","volume":"79","author":"Teo","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001430_bib89","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2015.05.009","article-title":"Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors","volume":"152","author":"Terada","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.123.001430_bib90","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s40262-022-01144-z","article-title":"Evaluation of safety and clinically relevant drug-drug interactions with tucatinib in healthy volunteers","volume":"61","author":"Topletz-Erickson","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001430_bib91","doi-asserted-by":"crossref","DOI":"10.21037\/tcr.2017.09.09","article-title":"The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology","volume":"6","author":"Touma","year":"2017","journal-title":"Transl Cancer Res"},{"key":"10.1124\/dmd.123.001430_bib92","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00044-022-02952-5","article-title":"Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations","volume":"31","author":"Wang","year":"2022","journal-title":"Med Chem Res"},{"key":"10.1124\/dmd.123.001430_bib93","article-title":"Drug-induced liver injury associated with dacomitinib: a case report","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1124\/dmd.123.001430_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1237234","article-title":"Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis","volume":"14","author":"Wei","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1124\/dmd.123.001430_bib95","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.drudis.2015.07.008","article-title":"Small-molecule kinase inhibitors: an analysis of FDA-approved drugs","volume":"21","author":"Wu","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1124\/dmd.123.001430_bib96","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.7150\/jca.26727","article-title":"HLA polymorphisms and TKI-induced liver injury in patients with cancer: a meta-analysis","volume":"10","author":"Xiang","year":"2019","journal-title":"J Cancer"},{"key":"10.1124\/dmd.123.001430_bib97","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol"},{"key":"10.1124\/dmd.123.001430_bib98","doi-asserted-by":"crossref","first-page":"15090","DOI":"10.1002\/cam4.6180","article-title":"Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: a systematic review and meta-analysis","volume":"12","author":"Yu","year":"2023","journal-title":"Cancer Med"},{"key":"10.1124\/dmd.123.001430_bib99","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.123.001430_bib100","article-title":"Drug-drug interaction potentials of tyrosine kinase inhibitors via inhibition of UDP-glucuronosyltransferases","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.123.001430_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312808","article-title":"Cytochrome P450 enzymes and drug metabolism in humans","volume":"22","author":"Zhao","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.123.001430_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108256","article-title":"Recent advances in metabolism and toxicity of tyrosine kinase inhibitors","volume":"237","author":"Zhao","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.123.001430_bib103","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001430_bib104","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/dmd.114.058750","article-title":"Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes","volume":"43","author":"Zientek","year":"2015","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562400686X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562400686X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.123.001430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:50:42Z","timestamp":1739955042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562400686X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S009095562400686X"],"URL":"https:\/\/doi.org\/10.1124\/dmd.123.001430","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kinase Inhibitors FDA Approved 2018\u20132023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.123.001430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}